The Potential Role of Adjuvant Chemoradiotherapy in Patients with Microscopically Positive (R1) Surgical Margins after Resection of Cholangiocarcinoma
(1) Background: Biliary tract cancers (BTCs) are a heterogeneous group of neoplasms with dismal prognosis and the role of adjuvant chemoradiotherapy in high-risk resected patients is unclear. (2) Methods: We retrospectively analyzed the outcomes of BTC patients who received curative intent surgery w...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-05-01
|
| Series: | Current Oncology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1718-7729/30/5/358 |
| _version_ | 1797600497364893696 |
|---|---|
| author | Andrea Palloni Silvia Bisello Ilaria Maggio Maria Massucci Andrea Galuppi Alessandro Di Federico Alessandro Rizzo Angela Dalia Ricci Giambattista Siepe Alessio Giuseppe Morganti Giovanni Brandi Giorgio Frega |
| author_facet | Andrea Palloni Silvia Bisello Ilaria Maggio Maria Massucci Andrea Galuppi Alessandro Di Federico Alessandro Rizzo Angela Dalia Ricci Giambattista Siepe Alessio Giuseppe Morganti Giovanni Brandi Giorgio Frega |
| author_sort | Andrea Palloni |
| collection | DOAJ |
| description | (1) Background: Biliary tract cancers (BTCs) are a heterogeneous group of neoplasms with dismal prognosis and the role of adjuvant chemoradiotherapy in high-risk resected patients is unclear. (2) Methods: We retrospectively analyzed the outcomes of BTC patients who received curative intent surgery with microscopically positive resection margins (R1) and adjuvant chemoradioradiotherapy (CCRT) or chemotherapy (CHT) from January 2001 to December 201. (3) Results: Out of 65 patients who underwent R1 resection, 26 received adjuvant CHT and 39 adjuvant CCRT. The median recurrence-free survival (RFS) in the CHT and CHRT groups was 13.2 and 26.8 months, respectively (<i>p</i> = 0.41). Median overall survival (OS) was higher in the CHRT group (41.9 months) as compared to the CHT group (32.2 months), but the difference was not statistically significant (HR 0.88; <i>p =</i> 0.7). A promising trend in favor of CHRT was observed in N0 patients. Finally, no statistically significant differences were observed between patients undergoing adjuvant CHRT after R1 resection and patients treated with chemotherapy alone after R0 surgery. (4) Conclusions: Our study did not show a significant survival benefit with adjuvant CHRT over CHT alone in BTC patients with positive resection margins, while a promising trend was observed. |
| first_indexed | 2024-03-11T03:49:59Z |
| format | Article |
| id | doaj.art-a721ba363748424bb0565315716bb2c5 |
| institution | Directory Open Access Journal |
| issn | 1198-0052 1718-7729 |
| language | English |
| last_indexed | 2024-03-11T03:49:59Z |
| publishDate | 2023-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Current Oncology |
| spelling | doaj.art-a721ba363748424bb0565315716bb2c52023-11-18T01:01:37ZengMDPI AGCurrent Oncology1198-00521718-77292023-05-013054754476610.3390/curroncol30050358The Potential Role of Adjuvant Chemoradiotherapy in Patients with Microscopically Positive (R1) Surgical Margins after Resection of CholangiocarcinomaAndrea Palloni0Silvia Bisello1Ilaria Maggio2Maria Massucci3Andrea Galuppi4Alessandro Di Federico5Alessandro Rizzo6Angela Dalia Ricci7Giambattista Siepe8Alessio Giuseppe Morganti9Giovanni Brandi10Giorgio Frega11Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, ItalyRadiation Oncology Center, Department of Experimental, Diagnostic and Specialty Medicine—DIMES, University of Bologna, S. Orsola-Malpighi Hospital, via Giuseppe Massarenti 9, 40138 Bologna, ItalyDepartment of Medical Oncology, Azienda USL, 40139 Bologna, ItalyMedical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, ItalyRadiation Oncology Center, Department of Experimental, Diagnostic and Specialty Medicine—DIMES, University of Bologna, S. Orsola-Malpighi Hospital, via Giuseppe Massarenti 9, 40138 Bologna, ItalyMedical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, ItalyStruttura Semplice Dipartimentale di Oncologia Medica per la Presa in Carico Globale del Paziente Oncologico “Don Tonino Bello”, I.R.C.C.S. Istituto Tumori “Giovanni Paolo II”, Viale Orazio Flacco 65, 70124 Bari, ItalyMedical Oncology Unit, National Institute of Gastroenterology, “Saverio de Bellis” Research Hospital, 70013 Castellana Grotte, ItalyRadiation Oncology Center, Department of Experimental, Diagnostic and Specialty Medicine—DIMES, University of Bologna, S. Orsola-Malpighi Hospital, via Giuseppe Massarenti 9, 40138 Bologna, ItalyRadiation Oncology Center, Department of Experimental, Diagnostic and Specialty Medicine—DIMES, University of Bologna, S. Orsola-Malpighi Hospital, via Giuseppe Massarenti 9, 40138 Bologna, ItalyMedical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, ItalyOsteoncology, Soft Tissue and Bone Sarcomas, Innovative Therapy Unit, IRCCS Istituto Ortopedico Rizzoli, 40136 Bologna, Italy(1) Background: Biliary tract cancers (BTCs) are a heterogeneous group of neoplasms with dismal prognosis and the role of adjuvant chemoradiotherapy in high-risk resected patients is unclear. (2) Methods: We retrospectively analyzed the outcomes of BTC patients who received curative intent surgery with microscopically positive resection margins (R1) and adjuvant chemoradioradiotherapy (CCRT) or chemotherapy (CHT) from January 2001 to December 201. (3) Results: Out of 65 patients who underwent R1 resection, 26 received adjuvant CHT and 39 adjuvant CCRT. The median recurrence-free survival (RFS) in the CHT and CHRT groups was 13.2 and 26.8 months, respectively (<i>p</i> = 0.41). Median overall survival (OS) was higher in the CHRT group (41.9 months) as compared to the CHT group (32.2 months), but the difference was not statistically significant (HR 0.88; <i>p =</i> 0.7). A promising trend in favor of CHRT was observed in N0 patients. Finally, no statistically significant differences were observed between patients undergoing adjuvant CHRT after R1 resection and patients treated with chemotherapy alone after R0 surgery. (4) Conclusions: Our study did not show a significant survival benefit with adjuvant CHRT over CHT alone in BTC patients with positive resection margins, while a promising trend was observed.https://www.mdpi.com/1718-7729/30/5/358cholangiocarcinomabiliary tract cancerschemo-radiotherapyradiotherapyR1 surgery |
| spellingShingle | Andrea Palloni Silvia Bisello Ilaria Maggio Maria Massucci Andrea Galuppi Alessandro Di Federico Alessandro Rizzo Angela Dalia Ricci Giambattista Siepe Alessio Giuseppe Morganti Giovanni Brandi Giorgio Frega The Potential Role of Adjuvant Chemoradiotherapy in Patients with Microscopically Positive (R1) Surgical Margins after Resection of Cholangiocarcinoma Current Oncology cholangiocarcinoma biliary tract cancers chemo-radiotherapy radiotherapy R1 surgery |
| title | The Potential Role of Adjuvant Chemoradiotherapy in Patients with Microscopically Positive (R1) Surgical Margins after Resection of Cholangiocarcinoma |
| title_full | The Potential Role of Adjuvant Chemoradiotherapy in Patients with Microscopically Positive (R1) Surgical Margins after Resection of Cholangiocarcinoma |
| title_fullStr | The Potential Role of Adjuvant Chemoradiotherapy in Patients with Microscopically Positive (R1) Surgical Margins after Resection of Cholangiocarcinoma |
| title_full_unstemmed | The Potential Role of Adjuvant Chemoradiotherapy in Patients with Microscopically Positive (R1) Surgical Margins after Resection of Cholangiocarcinoma |
| title_short | The Potential Role of Adjuvant Chemoradiotherapy in Patients with Microscopically Positive (R1) Surgical Margins after Resection of Cholangiocarcinoma |
| title_sort | potential role of adjuvant chemoradiotherapy in patients with microscopically positive r1 surgical margins after resection of cholangiocarcinoma |
| topic | cholangiocarcinoma biliary tract cancers chemo-radiotherapy radiotherapy R1 surgery |
| url | https://www.mdpi.com/1718-7729/30/5/358 |
| work_keys_str_mv | AT andreapalloni thepotentialroleofadjuvantchemoradiotherapyinpatientswithmicroscopicallypositiver1surgicalmarginsafterresectionofcholangiocarcinoma AT silviabisello thepotentialroleofadjuvantchemoradiotherapyinpatientswithmicroscopicallypositiver1surgicalmarginsafterresectionofcholangiocarcinoma AT ilariamaggio thepotentialroleofadjuvantchemoradiotherapyinpatientswithmicroscopicallypositiver1surgicalmarginsafterresectionofcholangiocarcinoma AT mariamassucci thepotentialroleofadjuvantchemoradiotherapyinpatientswithmicroscopicallypositiver1surgicalmarginsafterresectionofcholangiocarcinoma AT andreagaluppi thepotentialroleofadjuvantchemoradiotherapyinpatientswithmicroscopicallypositiver1surgicalmarginsafterresectionofcholangiocarcinoma AT alessandrodifederico thepotentialroleofadjuvantchemoradiotherapyinpatientswithmicroscopicallypositiver1surgicalmarginsafterresectionofcholangiocarcinoma AT alessandrorizzo thepotentialroleofadjuvantchemoradiotherapyinpatientswithmicroscopicallypositiver1surgicalmarginsafterresectionofcholangiocarcinoma AT angeladaliaricci thepotentialroleofadjuvantchemoradiotherapyinpatientswithmicroscopicallypositiver1surgicalmarginsafterresectionofcholangiocarcinoma AT giambattistasiepe thepotentialroleofadjuvantchemoradiotherapyinpatientswithmicroscopicallypositiver1surgicalmarginsafterresectionofcholangiocarcinoma AT alessiogiuseppemorganti thepotentialroleofadjuvantchemoradiotherapyinpatientswithmicroscopicallypositiver1surgicalmarginsafterresectionofcholangiocarcinoma AT giovannibrandi thepotentialroleofadjuvantchemoradiotherapyinpatientswithmicroscopicallypositiver1surgicalmarginsafterresectionofcholangiocarcinoma AT giorgiofrega thepotentialroleofadjuvantchemoradiotherapyinpatientswithmicroscopicallypositiver1surgicalmarginsafterresectionofcholangiocarcinoma AT andreapalloni potentialroleofadjuvantchemoradiotherapyinpatientswithmicroscopicallypositiver1surgicalmarginsafterresectionofcholangiocarcinoma AT silviabisello potentialroleofadjuvantchemoradiotherapyinpatientswithmicroscopicallypositiver1surgicalmarginsafterresectionofcholangiocarcinoma AT ilariamaggio potentialroleofadjuvantchemoradiotherapyinpatientswithmicroscopicallypositiver1surgicalmarginsafterresectionofcholangiocarcinoma AT mariamassucci potentialroleofadjuvantchemoradiotherapyinpatientswithmicroscopicallypositiver1surgicalmarginsafterresectionofcholangiocarcinoma AT andreagaluppi potentialroleofadjuvantchemoradiotherapyinpatientswithmicroscopicallypositiver1surgicalmarginsafterresectionofcholangiocarcinoma AT alessandrodifederico potentialroleofadjuvantchemoradiotherapyinpatientswithmicroscopicallypositiver1surgicalmarginsafterresectionofcholangiocarcinoma AT alessandrorizzo potentialroleofadjuvantchemoradiotherapyinpatientswithmicroscopicallypositiver1surgicalmarginsafterresectionofcholangiocarcinoma AT angeladaliaricci potentialroleofadjuvantchemoradiotherapyinpatientswithmicroscopicallypositiver1surgicalmarginsafterresectionofcholangiocarcinoma AT giambattistasiepe potentialroleofadjuvantchemoradiotherapyinpatientswithmicroscopicallypositiver1surgicalmarginsafterresectionofcholangiocarcinoma AT alessiogiuseppemorganti potentialroleofadjuvantchemoradiotherapyinpatientswithmicroscopicallypositiver1surgicalmarginsafterresectionofcholangiocarcinoma AT giovannibrandi potentialroleofadjuvantchemoradiotherapyinpatientswithmicroscopicallypositiver1surgicalmarginsafterresectionofcholangiocarcinoma AT giorgiofrega potentialroleofadjuvantchemoradiotherapyinpatientswithmicroscopicallypositiver1surgicalmarginsafterresectionofcholangiocarcinoma |